Navigation Links
Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
Date:10/31/2007

LAUSANNNE, Switzerland and CHIBA, Japan, October 31 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, and NanoCarrier Co., Ltd. (NanoCarrier) today announced the signature of a License and Supply Agreement for DACH-Platin Polymeric Micelle (Debio 0507/NC-4016), MediCelle(TM) technology, owned by NanoCarrier, currently in late preclinical development by Debiopharm for use in oncology. Phase I clinical studies are expected to start in 2008 in Europe and / or USA.

Under the terms of the agreement:

- NanoCarrier grants Debiopharm an exclusive license, with the right to sublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwide excluding Japan.

- Debiopharm will provide NanoCarrier exclusively with the starting material of DACH-platin, and NanoCarrier will manufacture and provide DACH-Platin Polymeric Micelle solely to Debiopharm.

- Debiopharm will cover costs related to the manufacture of DACH-Platin Polymeric Micelle and will pay NanoCarrier an up-front and milestones, as well as running royalties for the license.

- NanoCarrier will pay Debiopharm for the use of Debiopharm's data or intellectual property upon registration in Japan.

Debiopharm will be fully responsible for the development of DACH-Platin Polymeric Micelle. The collaboration between the two companies started in 2005, when NanoCarrier granted Debiopharm the exclusive option to license-in a DACH-platin-PEG-polyglutamic acid (DACH Platin MediCelle(TM)) from NanoCarrier, for use in oncology.

About DACH-Platin Micelle

DACH-platin is an active metabolite of Oxaliplatin, which shows stronger anticancer activity. Oxaliplatin is an anticancer drug effective against progressive and relapsed colon cancer. However, it may cause severe peripheral neuropathy like numbness. Because of its hydrophobic feature, it was difficult to formulate DACH-pl
'/>"/>

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ranbaxy to Market Debiopharms New Drug in India
2. Georgia: Indian doctors license cancelled
3. US Government Licenses New Hypertension Drug
4. Proposal to license Ayurveda Practitioners in the US
5. Genomatix Licensed By Bayer Healthcare
6. Panacea Biotec In-Licenses FMD Vaccine
7. Test for Esophageal Reflux Licensed to Bayer by University
8. Thailand Goes Ahead With Licenses for Generic Drugs
9. Swedish Biotech Licenses HIV Drug to China for Development
10. More Foreign Trained Doctors Receive Licenses
11. FDA Licenses First US Vaccine Against Avian Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Securityhunter has been awarded ... United States Department of Health and Human Services (HHS) ... MATOC was awarded through the General Services Administration (GSA) ... PSC, which is a fee-for-service agency. The award is ... and is an enterprise–wide physical security and security system ...
(Date:5/26/2015)... May 26, 2015 In God’s Unstoppable ... her as she writes an unforgettable story of how ... her life. The first black student to desegregate Evangeline ... beaten by some students, treated harshly by a few ... motivating personal phone conversation with Dr. Martin Luther King, ...
(Date:5/26/2015)... Over 700 doctors, nutritionists, nurses, and public ... secretaries of the U.S. Department of Agriculture and the ... to embrace the 2015 Dietary Guidelines Advisory Committee’s recommendations ... health, economic prosperity, and our nation’s food security. , ... including: Dr. David Katz, founding director of the Yale ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The American College ... join them for the Open House/Free Application Day on Wednesday, ... go until 4 p.m. and will be held at ACTCM ... CA. , After checking in, attendees will be greeted with ... a tour of the campus at 11:45 a.m. Lunch will ...
(Date:5/26/2015)... Irwin Gross, M.D., Accumen, Inc.’s ... Blood Management (PBM) initiative at Eastern Maine Medical Center ... more than 60 percent and improved patient outcomes over ... an article in the May 2015 edition of Transfusion, ... cell loss, less acute kidney injury and cut the ...
Breaking Medicine News(10 mins):Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Grace Sibley Releases Second Book, God's Unstoppable Favor 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 3Health News:ACTCM to Host Summer Open House 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3
... leadership and entrepreneurial expertise to ... ... the,creator of Dreamerz, the first ever all-natural sleep beverage, today,announced Gilbert ... newest member of the San Francisco-based company,s,Board of Directors. Pritchard brings ...
... issues while being treated by specialists for cancer improves ... the December 20 issue of the Journal of Clinical ... Indiana University School of Medicine, the Regenstrief Institute and ... to look at the effect of primary care on ...
... PALO ALTO, Calif., Dec. 27 Garry W. Rogerson,President ... at the 26th,annual JPMorgan Healthcare Conference in San Francisco ... A live webcast of the presentation will be ... . Go to, http://www.varianinc.com and click on "Investors." ...
... Computer Sciences,Corporation (NYSE: CSC ) ... extension to,a global information technology (IT) applications ... Under the five-year agreement, CSC will continue ... for Sun,s business,applications portfolios -- including finance, ...
... is also prone to pulmonary fibrosis, which has no cure ... of terrier could stop scientists from barking up the wrong ... , The illness, called idiopathic pulmonary fibrosis (IPF), affects 128,000 ... kills more than 40,000 people in the United States annually ...
... and Protect Themselves in New Year, VAN NUYS, ... they have cervical cancer/HPV this year,and nearly 4,000 will ... during Cervical Health Awareness Month, the National Cervical,Cancer Coalition ... the Pap test as a screening tool for cervical ...
Cached Medicine News:Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 2Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 3Health News:Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:Terriers Join Fight Against a Killer Disease in Humans 2Health News:Terriers Join Fight Against a Killer Disease in Humans 3Health News:Terriers Join Fight Against a Killer Disease in Humans 4Health News:National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month 2
(Date:5/26/2015)... ® Technologies, Inc., the leader in non-invasive, accelerated orthodontic ... to continued demand from orthodontists and patients for safe, ... locations in the U.S. and Canada ... the only FDA-cleared Class II medical device that has ... much as 50 percent.  A recent ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 /PRNewswire/ ... that Jennifer Simpson , Ph.D., M.S.N., C.R.N.P. ... by the Company,s Board of Directors, effective immediately.  ... Chief Executive Officer of Delcath since September 2014 ... from September 2013 to September 2014.  She joined ...
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
Breaking Medicine Technology:OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3Delcath Names Dr. Jennifer Simpson President And CEO 2Delcath Names Dr. Jennifer Simpson President And CEO 3Delcath Names Dr. Jennifer Simpson President And CEO 4LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
... study broadens Phase 3 clinical program to further evaluate the ... April 15 Pfizer (NYSE: PFE ) and ... announced the initiation of a 12-month, Phase 3 clinical trial ... CONCERT, is designed to evaluate the safety and efficacy of ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... study to evaluate the safety and tolerability of PCI-32765,an ... Btk,as a potential treatment for patients with relapsed or ... first Btk selective inhibitor to,be tested in humans, and ...
Cached Medicine Technology:Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 2Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 3Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: